Ireland-headquartered Shire (LSE: SHP) has been granted European Union marketing authorization for pancreatic cancer drug Onivyde (pegylated liposomal hydrochloride trihydrate), it has been announced.
The European Commission authorized the treatment as a second-line treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy.
Onivyde is the first and only treatment option in this patient population. Shire acquired certain ex-USa rights to the drug, along with its purchase of Baxalta, from Merrimack.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze